IP Library Granted Patent US 9,359,352
Granted Patent B2
US 9,359,352 · App. 14/801,218 · Granted Jun 7, 2016

Substituted benzimidazoles as PI3 kinase inhibitors

Inventors: Pingda Ren (San Diego, CA); Yi Liu (San Diego, CA); Liansheng Li (San Diego, CA); Katrina Chan (Fremont, CA); Troy Edward Wilson (Rolling Hills Estate, CA); Simon Fraser Campbell (Poole, GB)
Assignee: Intellikine LLC
C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,359,352
App. No.
14/801,218
Granted
Jun 7, 2016
Kind
B2
Abstract

The present invention provides substituted benzimidazole compounds of Formula I: wherein the variables R 1 , R 2 , W 1 , W 2 , W 3 , W 4 , W 5 , W 6 , W a , W b , W c and W d are defined herein. The compounds are useful as phosphoinositide 3-kinase (PI3 kinase) inhibitors.

Claims (31)

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

W 1 is N, NR 3 or CR 3 ; W 2 is N, NR 4 or CR 4 ; W 3 is N, NR 5 or CR 5 ; W 4 is N or NR 6 ; wherein no more than two N atoms are adjacent;

W 5 is N or NR 7 ; W 6 is N or CR 8 ; W a is CH; W b is CH; W c is NR 10 ; W d is N;

R 1 and R 2 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea or carbonate;

R 3 and R 4 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea or carbonate;

wherein R 4 is optionally substituted with one or more substituents selected from alkyl, alkenyl, alkynyl, cycloalkyl, heteroalkyl, heterocycloalkyl, heterocycloalkyloxy, aryl, arylalkyl, heteroaryl, heteroarylalkyl, acyl, alkoxy, amido, amino, sulfonamido, acyloxy, alkoxycarbonyl, halo, cyano, hydroxy, nitro, phosphate, urea, or carbonate; wherein said substituents are optionally further substituted with one or more of alkyl, alkoxy, amido, amino, sulfonamido, acyloxy, alkoxycarbonyl, halo, cyano, hydroxy, nitro, oxo, phosphate, urea or carbonate;

or R 3 and R 4 taken together form a cyclic moiety;

R 5 is hydrogen;

R 6 , R 7 , and R 8 are independently hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea or carbonate; and

R 10 is hydrogen, alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea or carbonate.

2. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound has the Formula:

3. The compound or pharmaceutically acceptable salt of claim 2 , wherein W 2 is CR 4 and R 4 is optionally substituted alkyl, heteroalkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, alkoxy, heterocycloalkyloxy, amido, amino, acyl, acyloxy, alkoxycarbonyl, sulfonamido, halo, cyano, hydroxy, nitro, phosphate, urea or carbonate.

4. The compound or pharmaceutically acceptable salt of claim 2 , wherein R 4 is optionally substituted aryl, heteroaryl, or heterocycloalkyl.

5. The compound or pharmaceutically acceptable salt of claim 4 , wherein R 4 is optionally substituted heterocycloalkyl.

6. The compound or pharmaceutically acceptable salt of claim 5 , wherein R 4 is 4-membered heterocycloalkyl, 5-membered heterocycloalkyl, 6-membered heterocycloalkyl, or 8-membered heterocycloalkyl.

7. The compound or pharmaceutically acceptable salt of claim 5 , wherein the optionally substituted heterocycloalkyl is morpholinyl, piperazinyl, azetidinyl, pyrrolidinyl, or piperidinyl.

8. The compound or pharmaceutically acceptable salt of claim 5 , wherein R 1 is hydrogen.

9. The compound or pharmaceutically acceptable salt of claim 8 , wherein R 2 is NH 2 .

10. The compound or pharmaceutically acceptable salt of claim 1 , wherein W 2 is CR 4 .

11. The compound or pharmaceutically acceptable salt of claim 10 , wherein R 4 is optionally substituted aryl, heteroaryl, or heterocycloalkyl.

12. The compound or pharmaceutically acceptable salt of claim 1 , wherein W 3 is CR 5 .

13. The compound or pharmaceutically acceptable salt of claim 1 , wherein W 4 is N.

14. The compound or pharmaceutically acceptable salt of claim 1 , wherein W 5 is N.

15. The compound or pharmaceutically acceptable salt of claim 1 , wherein W 2 and W 3 are CH.

16. The compound or pharmaceutically acceptable salt of claim 1 , wherein W 6 is CR 8 .

17. The compound or pharmaceutically acceptable salt of claim 1 , wherein W c is NR 10 and R 10 is alkyl or hydrogen.

18. The compound or pharmaceutically acceptable salt of claim 1 , wherein W 1 is CR 3 .

19. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 2 is amino.

20. The compound or pharmaceutically acceptable salt of claim 1 , wherein R 1 is hydrogen.

21. The compound or pharmaceutically acceptable salt of claim 1 , wherein the compound is selected from the group consisting of:

Assignments (2)
MERGER Recorded Jan 18, 2022
From: INTELLIKINE LLC
To: MILLENNIUM PHARMACEUTICALS, INC.
Reel/Frame 058678/0562 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2015
From: REN, PINGDA; LIU, YI; CHAN, KATRINA; LI, LIANSHENG; WILSON, TROY EDWARD; CAMPBELL, SIMON FRASER
To: INTELLIKINE, LLC
Reel/Frame 036948/0334 →
Continuity (5)
Division 13699611
Provisional Application 61347814 · May 24, 2010
Provisional Application 61426466 · Dec 22, 2010
Provisional Application 61445981 · Feb 23, 2011
Related Publication 20150322064A1 · Nov 12, 2015